By Antoinette Maassen van den Brink, Paolo Martelletti
Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.
Product Details
- Publisher : Springer; 1st ed. 2021 edition (April 29, 2021)
- Language : English
- Hardcover : 182 pages
- ISBN-10 : 3030690318
- ISBN-13 : 978-3030690311
- ISBN-13 : 9783030690311
- eText ISBN: 9783030690328
